Developmental role of macrophage cannabinoid-1 receptor signaling in type 2 diabetes

Diabetes

Volumn 66, Issue 4, 2017, Pages 994-1007

  Jourdan, Tony ^a   Szanda, Gergo ^a   Cinar, Resat ^a   Godlewski, Grzegorz ^a   Holovac, David J ^a   Park, Joshua K ^a   Nicoloro, Sarah ^b   Shen, Yuefei ^b   Liu, Jie ^a   Rosenberg, Avi Z ^c,d   Liu, Ziyi ^a   Czech, Michael P ^b   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; CCL2 PROTEIN, RAT; IL1B PROTEIN, RAT; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL POLARITY; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GENE SILENCING; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VIVO STUDY; INFLAMMATION; MACROPHAGE FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ZUCKER DIABETIC FATTY RAT; ANIMAL; GENE INACTIVATION; GENETICS; MACROPHAGE; METABOLISM; PANCREAS ISLET; ZUCKER RAT;

ANIMALS; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENE KNOCKOUT TECHNIQUES; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; INTERFERON REGULATORY FACTORS; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MACROPHAGES; MALE; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85019608681     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-1199     Document Type: Article

References (45)

1. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:193-205
2. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812
3. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19
4. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336
5. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-Associated macrophages in type 2 diabetes. Diabetes 2007;56:2356-2370
6. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462
7. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843
8. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013;17:475-490
9. Mazier W, Saucisse N, Gatta-Cherifi B, Cota D. The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease. Trends Endocrinol Metab 2015;26:524-537
10. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134
11. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006;368: 1660-1672
12. OHare JD, Zielinski E, Cheng B, Scherer T, Buettner C. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 2011;60:1055-1062
13. Furuya DT, Poletto AC, Freitas HS, Machado UF. Inhibition of cannabinoid CB1 receptor upregulates Slc2a4 expression via nuclear factor-kB and sterol regulatory element-binding protein-1 in adipocytes. J Mol Endocrinol 2012;49:97-106
14. Eckardt K, Sell H, Taube A, et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009;52:664-674
15. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169
16. Miranville A, Herling AW, Biemer-Daub G, Voss MD. Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages. Obesity (Silver Spring) 2010;18:2247-2254
17. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-2966
18. Tam J, Cinar R, Liu J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012;16: 167-179
19. Jourdan T, Godlewski G, Cinar R, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013;19:1132-1140
20. Schäfer A, Pfrang J, Neumöller J, Fiedler S, Ertl G, Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008;154:1047-1054
21. Jourdan T, Szanda G, Rosenberg AZ, et al. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci U S A 2014;111:E5420-E5428
22. Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011;12:231-238
23. Dalmas E, Toubal A, Alzaid F, et al. Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat Med 2015;21:610-618
24. Godlewski G, Jourdan T, Szanda G, et al. Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue. Sci Rep 2015;5:14953
25. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997;20:1087-1092
26. Iyer MR, Cinar R, Liu J, et al. Structural basis of species-dependent differential affinity of 6-Alkoxy-5-Aryl-3-pyridinecarboxamide cannabinoid-1 receptor antagonists. Mol Pharmacol 2015;88:238-244
27. Duran-Struuck R, Dysko RC. Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies. J Am Assoc Lab Anim Sci 2009;48:11-22
28. Buehler E, Chen Y-C, Martin S. C911: A bench-level control for sequence specific siRNA off-Target effects. PLoS One 2012;7:e51942
29. Tesz GJ, Aouadi M, Prot M, et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 2011;436:351-362
30. Liu J, Zhou L, Xiong K, et al. Hepatic cannabinoid receptor-1 mediates dietinduced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142:1218-1228.e1
31. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51:55-65
32. Taylor-Fishwick DA, Weaver J, Glenn L, et al. Selective inhibition of 12-lipoxygenase protects islets and beta cells from inflammatory cytokinemediated beta cell dysfunction. Diabetologia 2015;58:549-557
33. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122:787-795
34. Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458: 1180-1184
35. Eguchi K, Manabe I, Oishi-Tanaka Y, et al. Saturated fatty acid and TLR signaling link b cell dysfunction and islet inflammation. Cell Metab 2012;15:518-533
36. Shahzad K, Bock F, Dong W, et al. Nlrp3-inflammasome activation in nonmyeloid-derived cells aggravates diabetic nephropathy. Kidney Int 2015;87:74-84
37. Li Z, Schmidt SF, Friedman JM. Developmental role for endocannabinoid signaling in regulating glucose metabolism and growth. Diabetes 2013;62:2359-2367
38. Harvey J, McKenna F, Herson PS, Spanswick D, Ashford ML. Leptin activates ATP-sensitive potassium channels in the rat insulin-secreting cell line, CRIG1. J Physiol 1997;504:527-535
39. Ishida K, Murakami T, Mizuno A, Iida M, Kuwajima M, Shima K. Leptin suppresses basal insulin secretion from rat pancreatic islets. Regul Pept 1997; 70:179-182
40. Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl) 2012;90:175-186
41. Zhang C, Xiao C, Wang P, et al. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Hum Immunol 2014;75:289-296
42. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001;276:23382-23390
43. Han KH, Lim S, Ryu J, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 2009;84:378-386
44. Westwell-Roper C, Dai DL, Soukhatcheva G, et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011;187:2755-2765
45. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol 2010;11:897-904